Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

The safety of atypical antipsychotics: does QTc provide all the answers?

Nielsen J.

Expert Opin Drug Saf. 2011 May;10(3):341-4. doi: 10.1517/14740338.2011.576665. Epub 2011 Apr 20.

PMID:
21504386
2.
3.

[QTc-interval prolongation in therapy with atypical antipsychotics--results of an open, non-randomized survey].

Finzel M, Fric M, Laux G.

Psychiatr Prax. 2004 Nov;31 Suppl 1:S178-80. German.

PMID:
15570546
4.

[Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].

Ames D, Camm J, Cook P, Falkai P, Gury C, Hurley R, Johnson G, Piepho R, Vieweg V; Cardiac Safety in Schizophrenia Group.

Encephale. 2002 Nov-Dec;28(6 Pt 1):552-62. French.

PMID:
12506268
5.

Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.

Haddad PM, Anderson IM.

Drugs. 2002;62(11):1649-71. Review.

PMID:
12109926
6.

Ziprasidone and the QTc interval: pharmacokinetic and pharmacodynamic considerations.

Kelly DL, Love RC.

Psychopharmacol Bull. 2001 Autumn;35(4):66-79. Review.

PMID:
12397857
7.

Schizophrenia, antipsychotic drugs, and cardiovascular disease.

Glassman AH.

J Clin Psychiatry. 2005;66 Suppl 6:5-10. Review.

PMID:
16107178
8.

A retrospective study of the safety of intramuscular ziprasidone in agitated elderly patients.

Greco KE, Tune LE, Brown FW, Van Horn WA.

J Clin Psychiatry. 2005 Jul;66(7):928-9.

PMID:
16013910
9.

The effect of sertindole on QTD and TPTE.

Nielsen J, Andersen MP, Graff C, Kanters JK, Hardahl T, Dybbro J, Struijk JJ, Meyer JM, Toft E.

Acta Psychiatr Scand. 2010 May;121(5):385-8. doi: 10.1111/j.1600-0447.2009.01534.x. Epub 2010 Jan 19.

PMID:
20085555
10.

A case series of drug-induced long QT syndrome and Torsade de Pointes.

Tong KL, Lau YS, Teo WS.

Singapore Med J. 2001 Dec;42(12):566-70.

PMID:
11989578
11.

Ziprasidone: the fifth atypical antipsychotic.

Caley CF, Cooper CK.

Ann Pharmacother. 2002 May;36(5):839-51. Review.

PMID:
11978164
12.

Assessing QT interval prolongation and its associated risks with antipsychotics.

Nielsen J, Graff C, Kanters JK, Toft E, Taylor D, Meyer JM.

CNS Drugs. 2011 Jun 1;25(6):473-90. doi: 10.2165/11587800-000000000-00000. Review.

PMID:
21649448
13.

[Antipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmia].

Gury C, Canceil O, Iaria P.

Encephale. 2000 Nov-Dec;26(6):62-72. Review. French.

PMID:
11217540
14.

Torsades de pointes associated with ziprasidone.

Heinrich TW, Biblo LA, Schneider J.

Psychosomatics. 2006 May-Jun;47(3):264-8. No abstract available.

PMID:
16684946
15.

Clinical characteristics of patients with drug-induced QT interval prolongation and torsade de pointes: identification of risk factors.

Letsas KP, Efremidis M, Kounas SP, Pappas LK, Gavrielatos G, Alexanian IP, Dimopoulos NP, Filippatos GS, Sideris A, Kardaras F.

Clin Res Cardiol. 2009 Apr;98(4):208-12. doi: 10.1007/s00392-008-0741-y. Epub 2008 Nov 24.

PMID:
19031039
16.

QT prolongation and Torsades de Pointes following overdose of ziprasidone and amantadine.

Manini AF, Raspberry D, Hoffman RS, Nelson LS.

J Med Toxicol. 2007 Dec;3(4):178-81. No abstract available.

17.

Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics.

Czekalla J, Kollack-Walker S, Beasley CM Jr.

J Clin Psychiatry. 2001;62 Suppl 2:35-40. Review.

PMID:
11232751
18.

QTc prolongation, torsades de pointes, and psychotropic medications.

Beach SR, Celano CM, Noseworthy PA, Januzzi JL, Huffman JC.

Psychosomatics. 2013 Jan-Feb;54(1):1-13. doi: 10.1016/j.psym.2012.11.001. Review.

PMID:
23295003
19.

Drug safety evaluation of ziprasidone.

Citrome L.

Expert Opin Drug Saf. 2011 May;10(3):437-48. doi: 10.1517/14740338.2011.560114. Epub 2011 Feb 19. Review.

PMID:
21332416
20.

QT interval duration and dispersion in children and adolescents treated with ziprasidone.

Correll CU, Lops JD, Figen V, Malhotra AK, Kane JM, Manu P.

J Clin Psychiatry. 2011 Jun;72(6):854-60. doi: 10.4088/JCP.10m05990yel. Epub 2011 Mar 8.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk